Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer.

Baron, D; Pasquier, D; Pace-Loscos, T; Vandendorpe, B; Schiappa, R; Ortholan, C; Hannoun-Levi, J M

Baron, D; Pasquier, D; Pace-Loscos, T; Vandendorpe, B; Schiappa, R; Ortholan, C; Hannoun-Levi, J M.

Afiliación

Baron D; Department of Radiotherapy, Centre Antoine Lacassagne, University Cote d'Azur, Nice, France.
Pasquier D; Department of Radiotherapy Centre Oscar Lambret, Lille, France.
Pace-Loscos T; Biostatistic unit Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France.
Vandendorpe B; Department of Radiotherapy Centre Oscar Lambret, Lille, France.
Schiappa R; Biostatistic unit Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France.
Ortholan C; Department of Radiotherapy Centre Hospitalier Princesse Grace, Monaco.
Hannoun-Levi JM; Department of Radiotherapy, Centre Antoine Lacassagne, University Cote d'Azur, Nice, France.

Clin Transl Radiat Oncol ; 43: 100673, 2023 Nov.

Article en En | MEDLINE | ID: mdl-37701481

Palabras clave

Androgen deprivation therapy; Oligometastatic prostate cancer; Stereotactic body radiation therapy; Systemic therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Idioma: En Revista: Clin Transl Radiat Oncol Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google